Combination Therapy of Monobenzone and Imiquimod with Standard Care for Advanced or Metastatic Malignant Melanoma

The primary objective of this study is to evaluate the efficacy of combining monobenzone and imiquimod with the standard treatment regimen for malignant melanoma. Assessing this combination is clinically significant for determining potential improvements in the management of advanced melanoma or metastatic melanoma. 5

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with malignant melanoma. The cohort includes both male and female individuals within the age ranges of 3 to 17 years.

This clinical trial investigates the efficacy of combining monobenzone and imiquimod with the standard treatment for malignant melanoma. The research utilizes an ImMI protocol to evaluate these topical interventions in patients with advanced or metastatic disease. The study design includes an initial screening visit to assess eligibility, followed by a series of scheduled follow-up visits to monitor clinical progression and safety. The trial concludes with an end-of-study visit. The total duration of the research is estimated to be approximately two years. Early termination from the study may occur based on predefined clinical criteria or safety protocols.

Efficacy assessment in the context of this clinical trial for malignant melanoma is not specified.